Overview

A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
0
Participant gender:
Female
Summary
This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and safety study. Eligible patients are enrolled in a single group. The investigators propose to determine the efficacy and safety of low-dose metronomic chemotherapy with Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tao OUYANG
Treatments:
Capecitabine
Etoposide
Etoposide phosphate
Taxane
Criteria
Inclusion Criteria:

- female patients between 18 and 65 years old

- patients with metastatic breast cancer previousely treated with A/T

- able and willing to give consent to participate in the study

Exclusion Criteria:

- pregnant or lactating females

- other tumor history

- instable complication (e.g., myocardial infarction within 6 months,arrhythmia,
unstable diabetes, hypercalcemia) or uncontrolled infection

- concurrent disease or condition that would make the patient inappropriate for study
participation

- resist to participate in the study